Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma

@inproceedings{Gammons2014TargetingST,
  title={Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma},
  author={Melissa V. R. Gammons and Rudolf Lucas and Robert M. Dean and Sarah E Coupland and Sebastian Oltean and David W Bates},
  booktitle={British Journal of Cancer},
  year={2014}
}
Background:Current therapies for metastatic melanoma are targeted either at cancer mutations driving growth (e.g., vemurafenib) or immune-based therapies (e.g., ipilimumab). Tumour progression also requires angiogenesis, which is regulated by VEGF-A, itself alternatively spliced to form two families of isoforms, pro- and anti-angiogenic. Metastatic melanoma… CONTINUE READING